Targeting leukocyte trafficking for the treatment of inflammatory bowel disease

Clinical Pharmacology and Therapeutics

Volumn 97, Issue 1, 2015, Pages 22-28

  Arseneau, K O ^a   Cominelli, F ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALICAFORSEN; CD18 ANTIGEN; CELL ADHESION MOLECULE; CERTOLIZUMAB PEGOL; EFALIZUMAB; ELDELUMAB; ENEMA; ETROLIZUMAB; GOLIMUMAB; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; MESALAZINE; MONOCLONAL ANTIBODY; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; NATALIZUMAB; OZANIMOD; PF 00547659; PLACEBO; UNCLASSIFIED DRUG; UVOMORULIN; VASCULAR CELL ADHESION MOLECULE 1; VEDOLIZUMAB; VERCIRNON;

ARTICLE; CELL MIGRATION; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HUMAN; INFLAMMATORY BOWEL DISEASE; LEUKOCYTE; MULTICENTER STUDY (TOPIC); PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); ULCERATIVE COLITIS; ANIMAL; CELL MOTION; COLITIS, ULCERATIVE; DRUG DESIGN; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL MOVEMENT; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG DESIGN; HUMANS; LEUKOCYTES; MOLECULAR TARGETED THERAPY;

EID: 84927173528     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.6     Document Type: Article

References (44)

1. Rutgeerts, P. et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117, 761-769 (1999).
2. Present, D.H. et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340, 1398-1405 (1999).
3. Targan, S.R. et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337, 1029-1035 (1997).
4. Rutgeerts, P. et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353, 2462-2476 (2005).
5. Feagan, B.G. et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: Results from the CHARM study. Gastroenterology 135, 1493-1499 (2008).
6. Cominelli, F. Inhibition of leukocyte trafficking in inflammatory bowel disease. N Engl J Med 369, 775-776 (2013).
7. Springer, T.A. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. Cell 76, 301-314 (1994).
8. Malizia, G. et al. Expression of leukocyte adhesion molecules by mucosal mononuclear phagocytes in inflammatory bowel disease. Gastroenterology 100, 150-159 (1991).
9. Wong, P.Y. et al. Antibodies to ICAM-1 ameliorate inflammation in acetic acid induced inflammatory bowel disease. Adv Prostagland Thromboxane Leukot Res 23, 337-339 (1995).
10. Taniguchi, T. et al. Effects of the anti-ICAM-1 monoclonal antibody on dextran sodium sulphate-induced colitis in rats. J Gastroenterol Hepatol 13, 945-949 (1998).
11. Hamamoto, N., Maemura, K., Hirata, I., Murano, M., Sasaki, S. & Katsu, K. Inhibition of dextran sulphate sodium (DSS)-induced colitis in mice by intracolonically administered antibodies against adhesion molecules (endothelial leucocyte adhesion molecule-1 (ELAM-1) or intercellular adhesion molecule-1 (ICAM-1)). Clin Exp Immunol 117, 462-468 (1999).
12. Bendjelloul, F. et al. Intercellular adhesion molecule-1 (ICAM-1) deficiency protects mice against severe forms of experimentally induced colitis. Clin Exp Immunol 119, 57-63 (2000).
13. Bennett, C.F. et al. An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice. J Pharmacol Exp Ther 280, 988-1000 (1997).
14. Schreiber, S. et al. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology 120, 1339-1346 (2001).
15. Yacyshyn, B.R. et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 51, 30-36 (2002).
16. Gewirtz, A.T. & Sitaraman, S. Alicaforsen. Isis Pharmaceuticals. Curr Opin Investig Drugs 2, 1401-1406 (2001).
17. van Deventer, S.J., Tami, J.A. & Wedel, M.K. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut 53, 1646-1651 (2004).
18. Miner, P.B., Jr., Wedel, M.K., Xia, S. & Baker, B.F. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: A randomized, double-blind, active-controlled trial. Aliment Pharmacol Ther 23, 1403-1413 (2006).
19. van Deventer, S.J., Wedel, M.K., Baker, B.F., Xia, S., Chuang, E. & Miner, P.B., Jr. A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Aliment Pharmacol Ther 23, 1415-1425 (2006).
20. Miner, P., Wedel, M., Bane, B. & Bradley, J. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment Pharmacol Ther 19, 281-286 (2004).
21. James, D.G., Seo da, H., Chen, J., Vemulapalli, C. & Stone, C.D. Efalizumab, a human monoclonal anti-CD11a antibody, in the treatment of moderate to severe Crohn's Disease: An open-label pilot study. Dig Dis Sci 56, 1806-1810 (2011).
22. Schwab, N. et al. Fatal PML associated with efalizumab therapy: Insights into integrin alphaLbeta2 in JC virus control. Neurology 78, 458-67; discussion 65 (2012).
23. Podolsky, D.K. et al. Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody. J Clin Invest 92, 372-380 (1993).
24. Picarella, D., Hurlbut, P., Rottman, J., Shi, X., Butcher, E. & Ringler, D.J. Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD41 T cells. J Immunol 158, 2099-2106 (1997).
25. Shigematsu, T., Specian, R.D., Wolf, R.E., Grisham, M.B. & Granger, D.N. MAdCAM mediates lymphocyte-endothelial cell adhesion in a murine model of chronic colitis. Am J Physiol Gastrointest Liver Physiol 281, G1309-1315 (2001).
26. Kato, S. et al. Amelioration of murine experimental colitis by inhibition of mucosal addressin cell adhesion molecule-1. J Pharmacol Exp Ther 295, 183-189 (2000).
27. Hokari, R. et al. Involvement of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in the pathogenesis of granulomatous colitis in rats. Clin Exp Immunol 126, 259-265 (2001).
28. Goto, A. Arimura, Y., Shinomura, Y., Imai, K. & Hinoda, Y. Antisense therapy of MAdCAM-1 for trinitrobenzenesulfonic acid-induced murine colitis. Inflamm Bowel Dis 12, 758-765 (2006).
29. Briskin, M. et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 151, 97-110 (1997).
30. Connor, E.M., Eppihimer, M.J., Morise, Z., Granger, D.N. & Grisham, M.B. Expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in acute and chronic inflammation. J Leukocyte Biol 65, 349-355 (1999).
31. Ghosh, S. et al. Natalizumab for active Crohn's disease. N Engl J Med 348, 24-32 (2003).
32. Sandborn, W.J. et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 353, 1912-1925 (2005).
33. Targan, S.R. et al. Natalizumab for the treatment of active Crohn's disease: Results of the ENCORE Trial. Gastroenterology 132, 1672-1683 (2007).
34. Van Assche, G. et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353, 362-368 (2005).
35. Feagan, B.G. et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 369, 699-710 (2013).
36. Sandborn, W.J. et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 369, 711-721 (2013).
37. Vermeire, S. et al. Etrolizumab as induction therapy for ulcerative colitis: A randomised, controlled, phase 2 trial. Lancet 384, 309-318 (2014).
38. Pullen, N. et al. Pharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibody. Br J Pharmacol 157, 281-293 (2009).
39. Arseneau, K.O. & Cominelli, F. Vercirnon for the treatment of Crohn's disease. Expert Opin Investig Drugs 22, 907-913 (2013).
40. Keshav, S. et al. A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease. PloS One 8, e60094 (2013).
41. Kanaya, S.M. ChemoCentryx Announces GlaxoSmithKline's Release of Top-Line Results From the SHIELD-1 Phase III Study of Vercirnon. (2013). Accessed August 23, 2013.
42. Grimm, M.C. & Doe, W.F. Chemokines in inflammatory bowel disease mucosa: Expression of RANTES, macrophage inflammatory protein (MIP)21alpha, MIP-1beta, and gamma-interferon-inducible protein-10 by macrophages, lymphocytes, endothelial cells, and granulomas. Inflamm Bowel Dis 2, 88-96 (1996).
43. Ostvik, A.E. et al. Mucosal toll-like receptor 3-dependent synthesis of complement factor B and systemic complement activation in inflammatory bowel disease. Inflamm Bowel Dis 20, 995-1003 (2014).
44. Mayer, L. et al. Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: A phase II randomised study. Gut 63, 442-450 (2014).